IRVINE, Calif.--(BUSINESS WIRE)--Feb. 11, 2019--
Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer
of innovative treatments for aortic disorders, announced today the grant
of inducement equity awards to eight newly hired employees (the
“Awardees”). The awards were approved by the Company’s Compensation
Committee, which is comprised of independent Directors, on January 31,
2019, as an inducement material to the Awardees’ entry into employment
with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4).
The inducement grants to the Awardees consisted of options (the
“Options”) to purchase up to an aggregate of 434,500 shares of the
Company’s common stock, par value $0.001 per share (“Common Stock”), at
an exercise price of $0.7575 per share. The date of grant for the awards
was January 31, 2019. The exercise price of the Options is equal to the
closing price per share of the Company’s Common Stock as reported by
NASDAQ on January 31, 2019.
One-third (33%) of the shares subject to the Options shall vest on the
first anniversary of the grant date, with the remaining shares vesting
in twenty-four (24) equal, consecutive, monthly installments as measured
from the first anniversary of the grant date.
Endologix, Inc. develops, manufactures, markets and sells innovative
medical devices for the treatment of aortic disorders. The Company's
products are intended for the minimally invasive endovascular treatment
of abdominal aortic aneurysms (AAA). AAA occurs when a portion of the
abdominal aorta bulges into an aneurysm because of a weakening of the
vessel wall, which may result in life threatening internal bleeding upon
rupture. The overall patient mortality rate for ruptured AAA is
approximately 80%, making it among the leading causes of death in
the United States. For more information, visit www.endologix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190211005477/en/
Source: Endologix, Inc.
Vaseem Mahboob, CFO